Comparative Pharmacology
Head-to-head clinical analysis: GLATIRAMER ACETATE versus TECFIDERA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLATIRAMER ACETATE versus TECFIDERA.
GLATIRAMER ACETATE vs TECFIDERA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glatiramer acetate is a mixture of synthetic polypeptides composed of four amino acids (L-glutamic acid, L-lysine, L-alanine, and L-tyrosine). Its mechanism is not fully understood but is thought to modulate the immune system by inducing antigen-specific suppressor T cells, shifting the cytokine profile from pro-inflammatory (Th1) to anti-inflammatory (Th2), and promoting neuroprotection through increased brain-derived neurotrophic factor (BDNF) production.
Dimethyl fumarate (DMF) is a methyl ester of fumaric acid. The exact mechanism of action in multiple sclerosis is unknown. It is thought to activate the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway, which induces antioxidant response elements and upregulates cytoprotective genes, reducing oxidative stress and inflammation.
20 mg subcutaneously once daily for relapsing forms of multiple sclerosis.
240 mg orally twice daily.
None Documented
None Documented
Terminal half-life is approximately 1-2 hours for the parent compound; however, clinical effects persist for days to weeks due to immunological mechanisms (e.g., antigen-specific T-cell modulation).
The terminal elimination half-life of monomethyl fumarate (MMF) is approximately 1 hour. Due to rapid metabolism and elimination, MMF does not accumulate with multiple doses. No context of clinical significance is observed for accumulation.
Primarily renal excretion of intact glatiramer acetate and its metabolites; minimal biliary/fecal elimination. Exact percentages not established due to extensive metabolism.
Dimethyl fumarate is extensively metabolized; less than 1% is excreted unchanged in urine. The major metabolite, monomethyl fumarate, is further metabolized via the tricarboxylic acid cycle. Excretion occurs primarily as CO2 via exhalation, with about 60% of a dose recovered as CO2. Renal excretion accounts for approximately 16% of the dose as metabolites, and fecal excretion accounts for about 1%.
Category A/B
Category C
Immunomodulator
Immunomodulator, Fumaric Acid Derivative